FindTrial
Sign In

Iron therapy

DRUG4 trials

Sponsors

GlaxoSmithKline

Conditions

AnaemiaAspergillosis, Allergic Bronchopulmonary

Phase 3

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
CompletedNCT02876835
GlaxoSmithKlineAnaemia
Start: 2016-09-27End: 2021-04-19Updated: 2024-04-02
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
CompletedNCT02879305
GlaxoSmithKlineAnaemia, Aspergillosis, Allergic Bronchopulmonary
Start: 2016-09-28End: 2020-11-09Updated: 2021-12-03
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)
CompletedNCT03029208
GlaxoSmithKlineAnaemia
Start: 2017-05-11End: 2020-09-24Updated: 2021-10-20
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)
CompletedNCT03409107
GlaxoSmithKlineAnaemia
Start: 2018-03-05End: 2020-10-07Updated: 2024-04-02

Related Papers

Association of Different Definitions of Erythropoiesis-Stimulating Agent Hyporesponsiveness with Major Adverse Cardiovascular Events
Kidney3602025-05-071 citations
Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial
Nephrology Dialysis Transplantation2024-11-21
#3807 HEART FAILURE IN ASCEND-ND AND ASCEND-D
Nephrology Dialysis Transplantation2023-06-01
#3715 THE EFFECT OF DAPRODUSTAT ON INTRAVENOUS IRON USE IN PATIENTS WITH CKD-RELATED ANAEMIA ON DIALYSIS IN THE ASCEND TRIALS
Nephrology Dialysis Transplantation2023-06-01
Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)
American Journal of Nephrology2023-01-0111 citations
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents—<i>post hoc</i> analyses of the ASCEND-ND and ASCEND-D trials
Nephrology Dialysis Transplantation2022-12-2410 citations
Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials
European Heart Journal2022-10-018 citations
Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial
European Heart Journal2022-10-01
Efficacité du daprodustat sur le taux d’Hb et sécurité cardiovasculaire dans les études ASCEND-ND, -D, et -ID
Néphrologie & Thérapeutique2022-09-01
MO530: Daprodustat is not Associated With an Increased Risk of Cancer: Results From the ASCEND-D and ASCEND-ND Trials
Nephrology Dialysis Transplantation2022-05-012 citations
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients
JAMA Internal Medicine2022-04-0469 citations
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis
New England Journal of Medicine2021-11-05220 citations
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis
New England Journal of Medicine2021-11-05210 citations
MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS
Nephrology Dialysis Transplantation2021-05-011 citations
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial
Nephrology Dialysis Transplantation2021-03-1817 citations